Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL: Barclays 26th Annual Global Healthcare Con
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders are probably feeling a little disappointed, since its shares...
Today is shaping up negative for Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders, with the analysts...
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript February 29, 2024 Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. ABUS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and […]
Q4 2023 Arbutus Biopharma Corp Earnings Call
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 54.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ABUS Announces Decrease in Annual Revenue and Net Loss for 2023
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial with imdusiran in first half of 2024 Claim Construction for Moderna LNP litigation occurred on February 8, 2024; trial date set for April 21, 2025 Strong financial position with cash and investments of $132M; cash runway into Q1 2026 Conference Call and Webcast Today at 8:45 am ET WARMINSTER, Pa., F
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows: •
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders should be happy to see the share price up 25% in the last...